Wall Street Zen lowered shares of Prestige Consumer Healthcare (NYSE:PBH – Free Report) from a buy rating to a hold rating in a research note issued to investors on Saturday.
A number of other equities research analysts have also commented on the company. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank Of Canada raised Prestige Consumer Healthcare to a “hold” rating in a research report on Thursday, May 8th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $93.33.
View Our Latest Analysis on PBH
Prestige Consumer Healthcare Price Performance
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to analysts’ expectations of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company’s quarterly revenue was down 6.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.90 earnings per share. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.
Institutional Investors Weigh In On Prestige Consumer Healthcare
Several large investors have recently added to or reduced their stakes in PBH. UMB Bank n.a. increased its holdings in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after acquiring an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Maseco LLP bought a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $27,000. Opal Wealth Advisors LLC bought a new position in Prestige Consumer Healthcare in the 1st quarter worth about $38,000. Finally, First Horizon Advisors Inc. boosted its stake in Prestige Consumer Healthcare by 294.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after purchasing an additional 447 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Stories
- Five stocks we like better than Prestige Consumer Healthcare
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- MNDY Stock Has a Case of the Mondays—Buy Before the Rebound
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- IPO Market Stays Hot With These 2 Debuting Stocks
- How to find penny stocks to invest and trade
- Taiwan Semiconductor Stock: Own It, Don’t Trade It
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.